Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Targeted Therapies in Inflammatory Complex Multi Organ Disease
NCT03651518Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2020
- Primary completion
- Nov 2025
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label trial of anakinra, adalimumab, ustekinumab, secukinumab, tocilizumab and 1 more in Inflammatory Disorders and autoimmune disease (6 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Composite clinico-biological evaluation at 6 months. Started Oct 2020; status: completed.
02
Drugs
03
Conditions
Inflammatory Disordersautoimmune disease
Beyond the preview
Go deeper on NCT03651518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03651518.